Stock market analysts watching Fate Therapeutics, Inc. (FATE) have recently changed their ratings on the stock. The latest reports which are outstanding on Monday 17th of July state 2 analysts have a rating of “strong buy”, 4 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Latest stock market analyst ratings:

03/20/2017 – Fate Therapeutics, Inc. had its “” rating reiterated by analysts at H.C. Wainwright. They now have a USD 6 price target on the stock.

03/17/2017 – Fate Therapeutics, Inc. had its “” rating reiterated by analysts at Wedbush. They now have a USD 7 price target on the stock.

03/17/2017 – Fate Therapeutics, Inc. had its “” rating reiterated by analysts at BMO Capital Markets. They now have a USD 7 price target on the stock.

09/22/2016 – Roth Capital began new coverage on Fate Therapeutics, Inc. giving the company a “” rating. They now have a USD 8 price target on the stock.

06/20/2016 – Fate Therapeutics, Inc. had its “” rating reiterated by analysts at Leerink Swann. They now have a USD 4 price target on the stock.

12/03/2015 – Wells Fargo began new coverage on Fate Therapeutics, Inc. giving the company a “” rating.

11/04/2015 – Fate Therapeutics, Inc. had its “” rating reiterated by analysts at Cowen.

10/06/2015 – Raymond James began new coverage on Fate Therapeutics, Inc. giving the company a “” rating. They now have a USD 8 price target on the stock.

05/12/2015 – Fate Therapeutics, Inc. was downgraded to “” by analysts at Zacks. They now have a USD 6.25 price target on the stock.

Fate Therapeutics, Inc. has a 50 day moving average of 3.41 and a 200 day moving average of 3.65. The stock’s market capitalization is 127.93M, it has a 52-week low of 1.55 and a 52-week high of 5.68.

The share price of the company (FATE) was down -1.90% during the last trading session, with a high of 3.17 and the volume of Fate Therapeutics, Inc. shares traded was 192278.

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.